Press Releases

Press Releases

Press Releases

Date Title and Summary Additional Formats
Aug 02, 2018
Genomic Health Announces Second Quarter 2018 Financial Results and Reports Recent Business Progress
Reported Record Revenue of $95.6M and Delivered 14 Percent Growth on a Pre-606 Adjusted Revenue Basis Delivered $8.3M Profit on a GAAP Basis and $9.4M Profit on a Non-GAAP Basis 12th Consecutive Quarter of Improved Non-GAAP Profitability REDWOOD CITY, Calif. , Aug.
Jul 26, 2018
Genomic Health to Announce Second Quarter 2018 Financial Results and Host Conference Call on Thursday, August 2, 2018
REDWOOD CITY, Calif. , July 26, 2018 /PRNewswire/ --  Genomic Health, Inc.  (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Thursday, August 2 at 4:30 p.m. Eastern Time to discuss its second quarter 2018 financial results. The call and webcast will follow
Jun 03, 2018
Landmark TAILORx Results, Published Today in The New England Journal of Medicine, Demonstrate the Oncotype DX Breast Recurrence Score® Test Definitively Identifies the 70% of Women with Early-stage Breast Cancer Who Receive No Benefit from Chemotherapy, and the 30% of Women for Whom Chemotherapy Benefit Can be Life-saving
Independently Led by ECOG-ACRIN Research Group, TAILORx Prospective, Randomized Phase III Clinical Trial Results to be Presented Today in the Plenary Session at ASCO Annual Meeting TAILORx-defined Cutoff for Definitively Determining Chemotherapy Benefit with Oncotype DX® Usher in a New Era in the
May 30, 2018
Genomic Health to Present at Jefferies 2018 Global Healthcare Conference
REDWOOD CITY, Calif. , May 30, 2018 /PRNewswire/ --  Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present at the Jefferies 2018 Global Healthcare Conference in New York City on Wednesday, June 6, 2018 at 8:30 a.m. Eastern Time . To access the live and subsequently archived
May 21, 2018
New Data Reinforce Positive Impact of the Oncotype DX® Genomic Prostate Score™ Test in Guiding Treatment Decisions
Studies in Over 30,000 Newly Diagnosed Prostate Cancer Patients Presented at American Urological Association (AUA) Annual Meeting Confirm Utility of GPS™ Test in Optimizing Cancer Care REDWOOD CITY, Calif. , May 21, 2018 /PRNewswire/ -- Genomic Health , Inc. (NASDAQ: GHDX) today announced results
May 09, 2018
Genomic Health to Present at Bank of America Merrill Lynch 2018 Health Care Conference
REDWOOD CITY, Calif. , May 9, 2018 /PRNewswire/ --  Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present at the Bank of America Merrill Lynch 2018 Health Care Conference in Las Vegas on Wednesday, May 16, 2018 at 3:00 p.m. Pacific Time .
May 02, 2018
Genomic Health Announces First Quarter 2018 Financial Results and Reports Recent Business Progress
Reported Record Revenue of $92.6M and Delivered 13 Percent Revenue Growth on a Pre-606 Adjusted Basis
Reported Net Loss of $3.8M Including First Quarter Charge of $8.5M for Realignment of Resources
Delivered $4.6M Profit on a Non-GAAP Basis
Apr 26, 2018
Large Independent Study Using the Oncotype DX® Test Accepted for Presentation at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
REDWOOD CITY, Calif. , April 26, 2018 /PRNewswire/ --  Genomic Health, Inc.  (NASDAQ: GHDX) has been informed of the acceptance of the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, for presentation by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN).
Apr 25, 2018
Genomic Health to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 2, 2018
REDWOOD CITY, Calif. , April 25, 2018 /PRNewswire/ -- Genomic Health , Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Wednesday, May 2 at 4:30 p.m. Eastern Time to discuss its first quarter 2018 financial results. The call and webcast will follow the
Mar 15, 2018
Landmark TAILORx Results Aid in Assessing the Effect of Chemotherapy in Women with Early-stage Breast Cancer and Oncotype DX Breast Recurrence Score® Results of 11 to 25
Results from Large, Prospective Randomized Clinical Trial to be Submitted for Presentation at Upcoming Major Medical Meeting